Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 3Terminated 3Recruiting 3Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2mCRPC 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Leukemia 1Extensive Stage Lung Small Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 24Carboplatin 21Paclitaxel 20olaparib 19Magnetic Resonance Spectroscopy 14Bevacizumab 14Cyclophosphamide 12Specimen Handling 11Nivolumab 11Gemcitabine 11Taxes 10niraparib 8Cisplatin 8Biopsy 8liposomal doxorubicin 7fludarabine 7Surveys and Questionnaires 6Immunoglobulin G 6Doxorubicin 6Disulfides 6durvalumab 5palbociclib 4oregovomab 4X-Rays 4Ipilimumab 4mirvetuximab soravtansine 3ipatasertib 3defactinib 3cediranib 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Ovarian Neoplasms × talazoparib × Clear all
NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer

Phase 3 Active not recruiting
68 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡